Literature DB >> 11044464

Expression of sex steroid receptors and Ki-67 in the endometria of menorrhagic women: effects of intrauterine levonorgestrel.

R Hurskainen1, A Salmi, J Paavonen, J Teperi, E Rutanen.   

Abstract

The levonorgestrel-releasing intrauterine system (LNG-IUS) has proven to be the most effective medical treatment in reducing the amount of menstrual blood loss. However, the molecular mechanisms underlying menorrhagia and/or accounting for the therapeutic effect of the LNG-IUS are still obscure. In this study, we used immunohistochemistry to compare the distribution of sex steroid receptors and the proliferation marker Ki-67 in the endometria of women with and without menorrhagia before and after 6 and 12 months of treatment with an LNG-IUS. The study sample included 67 women (aged 35-49 years) who had spontaneous ovulatory cycles. In women with menorrhagia, secretory phase endometrium exhibited more proliferative activity than in women without menorrhagia. No significant differences were found in the immunoreactivity of the oestrogen or progesterone receptors in women either with or without menorrhagia suggesting that, in addition to endocrine hormones, other factors are involved in the regulation of endometrial proliferation and menstrual blood loss. A total of 35 women were treated with LNG-IUS. After 6 months use of an LNG-IUS, the immunoreactivity of both epithelial and stromal progesterone receptors, as well as those of epithelial Ki-67 declined, and no differences were detectable between the women in the menorrhagia and control groups. Breakthrough bleeding remained a problem for nine (26%) LNG-IUS users, with no association with the pre-treatment amount of bleeding. No significant differences were found in the parameters studied between the women with and without breakthrough bleeding 6 months after insertion of an LNG-IUS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044464     DOI: 10.1093/molehr/6.11.1013

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  5 in total

1.  Sex hormone regulation of survivin gene expression.

Authors:  Nancy H Nabilsi; Russell R Broaddus; Adrienne S McCampbell; Karen H Lu; Henry T Lynch; Lee-May Chen; David S Loose
Journal:  J Endocrinol       Date:  2010-08-26       Impact factor: 4.286

Review 2.  Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases.

Authors:  Mi-La Kim; Seok Ju Seong
Journal:  Obstet Gynecol Sci       Date:  2013-03-12

3.  Hormonal treatment for severe hydronephrosis caused by bladder endometriosis.

Authors:  Erkan Efe; Murat Bakacak; Salih Serin; Eyüp Kolus; Onder Ercan; Sefa Resim
Journal:  Case Rep Urol       Date:  2014-11-18

4.  Development of an animal experimental model to study the effects of levonorgestrel on the human endometrium.

Authors:  M-L Alvarez Gonzalez; C Galant; F Frankenne; M Nisolle; S Labied; J-M Foidart; E Marbaix; A Béliard
Journal:  Hum Reprod       Date:  2008-12-17       Impact factor: 6.918

5.  Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium.

Authors:  Ashley S Felix; Mia M Gaudet; Carlo La Vecchia; Christina M Nagle; Xiao Ou Shu; Elisabete Weiderpass; Hans Olov Adami; Shirley Beresford; Leslie Bernstein; Chu Chen; Linda S Cook; Immaculata De Vivo; Jennifer A Doherty; Christine M Friedenreich; Susan M Gapstur; Dierdre Hill; Pamela L Horn-Ross; James V Lacey; Fabio Levi; Xiaolin Liang; Lingeng Lu; Anthony Magliocco; Susan E McCann; Eva Negri; Sara H Olson; Julie R Palmer; Alpa V Patel; Stacey Petruzella; Jennifer Prescott; Harvey A Risch; Lynn Rosenberg; Mark E Sherman; Amanda B Spurdle; Penelope M Webb; Lauren A Wise; Yong-Bing Xiang; Wanghong Xu; Hannah P Yang; Herbert Yu; Anne Zeleniuch-Jacquotte; Louise A Brinton
Journal:  Int J Cancer       Date:  2014-09-30       Impact factor: 7.316

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.